drugset / Trial / NCT06510816

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816 ↗

Phase 3 Active not recruiting 659 enrolled Annexon, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Timeline

Start
2024-07-30
Primary completion
2026-10-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX007 Unknown — Intravitreal